A Department of Pediatrics, P & A Kyriafeou Children's Hospital, Athens, Greece.
Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S125-30. doi: 10.1016/S0168-8227(11)70028-6.
Continuous glucose monitoring system (CGMS) is a developing technology in the field of diabetes treatment since it enables patients to effectively control and adjust their insulin therapy. Clinical trials have shown its efficacy in lowering HbAlc significantly especially in adults with type 1 diabetes and those with HbAlc >8%. Improvement is sustained for at least one year. Conflicting data exist for children. Most recent studies agree that the nearly daily use of CGMS is accompanied by significant lowering of HbA1c independent of age. However, the randomized clinical trials have shown that the use of CGMS does not reduce significantly the number of severe hypoglycemic episodes as it is expected, but recent data indicate that it reduces the time spent in hypoglycemia. Accuracy remains a key issue for CGMS, particularly in children and adolescents who may have increased variability of blood glucose. CGMS cost is another barrier to the everyday use since reimbursement of CGM is limited to a few countries only. This review will focus on the present status of the use of CGMS in type 1 diabetes (T1D) patients.
连续血糖监测系统（CGMS）是糖尿病治疗领域的一项发展中的技术，因为它使患者能够有效地控制和调整胰岛素治疗。临床试验表明，它在降低 HbAlc 方面非常有效，特别是在 1 型糖尿病患者和 HbAlc>8%的患者中。这种改善至少持续一年。对于儿童，存在相互矛盾的数据。最近的大多数研究都认为，CGMS 的近乎每天使用伴随着 HbA1c 的显著降低，而与年龄无关。然而，随机临床试验表明，CGMS 的使用并没有像预期的那样显著减少严重低血糖发作的次数，但最近的数据表明，它减少了低血糖发生的时间。准确性仍然是 CGMS 的一个关键问题，特别是在血糖变化较大的儿童和青少年中。CGMS 的成本是日常使用的另一个障碍，因为只有少数国家对 CGMS 进行报销。这篇综述将重点介绍 CGMS 在 1 型糖尿病（T1D）患者中的使用现状。
